Search This Blog

Tuesday, August 4, 2026

Spyre completes enrollment in Phase 2 SKYWAY trial of SPY072 in rheumatic diseases

 

Spyre Therapeutics posts Q2 loss of $36.2M, beats estimates, ends quarter with $1.1B cash, completes Phase 2 SKYWAY enrollment

  • Q2 2026 results accompanied completion of enrollment in Phase 2 SKYWAY trial of SPY072 in rheumatic diseases.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)